New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
16:25 EDTMMM, AMGNAmgen appoints David Meline CFO
Amgen (AMGN) announced the appointment of David W. Meline as EVP and CFO, effective July 21. He will be responsible for Amgen's finance and investor relations operations, reporting to Robert A. Bradway, chairman and CEO. Meline will succeed Michael A. Kelly, who served as acting CFO since January 2014. Meline joins Amgen from 3M Company (MMM), where he most recently served SVP and CFO, responsible for all financial activities for 3M across 70 countries of operation.
News For AMGN;MMM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 27, 2015
16:31 EDTMMMOn The Fly: Closing Wrap
Subscribe for More Information
16:15 EDTAMGNAmgen submits applications in US and Europe for Kyprolis
Amgen and its subsidiary Onyx Pharmaceuticals announced the submission of a supplemental New Drug Application,sNDA to the U.S. Food and Drug Administration and a Marketing Authorization Application to the European Medicines Agency for Kyprolis for Injection to seek approval for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. In the U.S., the sNDA is designed to support the conversion of accelerated approval to full approval and expand the current approved indication. In the European Union, Kyprolis received orphan drug designation and the MAA has been granted accelerated assessment. The sNDA and MAA are based on data from the Phase 3 ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) trial and other relevant data. "Multiple myeloma is an incurable blood cancer that often becomes resistant to treatment, underscoring the need for new therapeutic options that provide deep and durable responses to extend the time patients live without their disease progressing," said Pablo J. Cagnoni, M.D., president, Onyx Pharmaceuticals, Inc. "The U.S. and EU submissions support our goal of bringing Kyprolis to patients with relapsed multiple myeloma."
16:06 EDTAMGNAmgen trades higher after hours, levels to watch
Subscribe for More Information
16:04 EDTAMGNAmgen backs FY15 EPS view $9.05-$9.40, consensus $9.29
Backs FY15 revenue view $20.8B-$21.3B, consensus $20.87B.
16:03 EDTAMGNAmgen reports Q4 EPS $2.16, consensus $2.05
Subscribe for More Information
15:35 EDTAMGNNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Apple (AAPL), consensus $2.60; AT&T (T), consensus 55c; Amgen (AMGN), consensus $2.05; Yahoo (YHOO), consensus 29c; ACE (ACE), consensus $2.29; Stryker (SYK), consensus $1.45; Western Digital (WDC), consensus $2.10; Electronic Arts (EA), consensus 92c; Juniper (JNPR), consensus 31c; Total System Services (TSS), consensus 53c; Freescale Semiconductor (FSL), consensus 33c; Amdocs (DOX), consensus 81c; VMware (VMW), consensus $1.07; International Game Technology (IGT), consensus 25c; United States Steel (X), consensus 87c; Cytec (CYT), consensus 61c.
12:57 EDTAMGNEarnings Preview: Amgen's Kyprolis, Prolia sales key for Q4 results
Subscribe for More Information
12:28 EDTMMMOn The Fly: Midday Wrap
Subscribe for More Information
09:43 EDTMMM3M Company sees Swiss franc immaterial to 2015 results
Subscribe for More Information
09:33 EDTMMM3M sees forex hurting EPS by about 20c y/y in 2015
Subscribe for More Information
09:25 EDTMMM3M Company says sees continued momentum in 2015
Subscribe for More Information
08:53 EDTMMM3M Company sees FY15 gross share repurchases $3B-$5B
Sees FY15 CapEx $1.5B-$1.7B. Sees further foreign currency headwinds being offset by lower than expected input costs in FY15. Says foreign currency translation expected to be a headwind of -4% to -5% in FY15. Sees FY tax rate 28%-29%. Comments from slides that will be presented on the Q4 earnings conference call.
07:32 EDTMMM3M Company sees FY15 EPS $8.00-$8.30, consensus $8.20
Subscribe for More Information
07:31 EDTMMM3M Company affirms FY15 performance expectations
Subscribe for More Information
07:31 EDTMMM3M Company reports Q4 EPS $1.81, consensus $1.80
Reports Q4 revenue $7.7B, consensus $7.77B. Organic local-currency sales grew 6.3 percent with acquisitions adding 0.1 percent to sales. Foreign currency translation reduced sales by 4.4 percent year-on-year.
January 26, 2015
15:40 EDTMMMNotable companies reporting before tomorrow's open
Subscribe for More Information
15:23 EDTMMM3M Company technical comments before results
The shares have a potential bearish head and shoulders top in development. The neckline for the pattern remains at considerable distance from current price at the $155 area. It would take more bearish news than current expectations would suggest to reach the neckline. Downside potential for the pattern, if it triggers, would be to the $142 area over time. It should be noted that on a long-term chart the price action of recent years has resulted in a near-vertical rise that appears unsustainable. If the news is more bullish than expected, resistance levels to watch as potential upside objectives would be at $165.99 and then at $168.16, the 52-week high and lifetime high. On a breakout above $168.16, a run to $170 to $175 may be possible.
January 22, 2015
10:03 EDTMMMOn the Fly: Analyst Initiation Summary
Subscribe for More Information
January 21, 2015
16:14 EDTMMM3M Company initiated with a Buy at UBS
Target $195.
10:16 EDTAMGNLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use